Overview
Abselion develops the Amperia benchtop platform using proprietary Redox Electrochemical Detection (RED) technology for fast, accurate quantification of proteins, antibodies, and viral vectors without optics or fluidics. The system simplifies workflows in life sciences, biotech, and therapeutic development with ready-to-use kits like Protein G for broad IgG subclass and species titre measurement. Based in Cambridge, UK, with a new US subsidiary, it supports research, process development, and bioprocessing for reliable data from complex samples.
Frequently asked questions
- What is Abselion's main technology and capabilities?
- Abselion's Amperia platform uses RED technology for automated, dip-and-read quantification of proteins, total antibodies via Protein G/A kits, and viral vectors, delivering real-time results without optics, fluidics, or specialist training.
- What regulatory or compliance features does Amperia offer?
- Amperia provides reproducible, accurate results from complex samples with intuitive software guidance, suitable for research and process development; specific regulatory certifications are not detailed, but it minimizes errors in bioprocessing workflows.
- Where does Abselion operate and provide support?
- Headquartered in Cambridge, UK, Abselion has launched a US subsidiary for localized technical expertise and collaboration with North American biotech and pharma partners.